The number of pipeline Wound Care Management products in 2021 saw an 56% rise globally when compared to Wound Care Management pipeline products in 2020, according to GlobalData’s pipeline products database. This compares to an 15% rise for all pipeline medical devices in 2021 compared to 2020.
The global Wound Care Management market was worth $30.54bn in 2020 and is expected to reach $31.98bn by 2025, according to GlobalData’s analysis.
Wound Care Management pipeline products by categories: Advanced Wound Management has the most devices
Looking at the device categories of pipeline products, Advanced Wound Management accounted for the largest proportion (39.32%) in 2021, followed by Wound Closure Devices (23.08%) and Tissue Engineered – Skin Substitutes (8.55%).
Of the global medical devices market value, the Wound Care Management market held a 6% share worth $30bn in 2021 and is expected to reach $31.98bn by 2025.
Wound Care Management development activity: Advanced stage of development leads
Devices at an advanced stage of development (in clinical trials, in the approval process, already approved in Europe or the rest of the world) accounted for 37.72% of medical devices in 2021, compared with 40.91% in 2020. The number of devices at the In Approval stage inclined by 29% in 2021, when compared with 2020.
The In Approval stage is considered to be the period where the manufacturer is waiting for final approval from regulators, following completion of the required development steps.
A decrease in products awaiting approval would indicate less new products entering the market in the coming months, while an increase indicates more devices entering the market, posing a market share threat to existing marketed devices.
North America tops pipeline Wound Care Management products activity
Comparing the number of pipeline Wound Care Management products activity in different regions of the globe, North America held the top position (69%) during 2021, followed by Asia-Pacific (17%), and Europe (11%).
On a country level, the US had the most pipeline Wound Care Management during the year, representing the largest share (68%) of Wound Care Management pipeline products. In second place was China (7%), followed by Japan (3%).
New pipeline Wound Care Management medical devices: Expected to be approved by 2025
According to GlobalData, approximately 50% of pipeline Wound Care Management in 2021 were expected to receive regulatory approval by the end of 2025. The leading categories for devices expected to receive regulatory approval by the end of 2025 was Hydrogels, at 5% of devices. Differences in regulatory approval timelines reflect the stage of development for a device, the device complexity or risk categorization (or device class) or if there are changes in regulatory oversight.
Osiris Therapeutics Inc tops Wound Care Management development in 2021
According to GlobalData, top ten medical device companies accounted for 22.22% of pipeline Wound Care Management activity during 2021. The leading company for developing Wound Care Management was Osiris Therapeutics Inc with 3.42%, followed by Octet Medical Inc at 2.56%.
Companies launching new medical devices are more likely to disrupt existing market share or are better able to defend existing share.
Company-developed pipeline products lead Wound Care Management in development
Looking at the share of activity in terms of Wound Care Management pipeline products developers, company-developed pipeline products accounted for a 77% share of the Wound Care Management medical devices market, while institute-developed pipeline products held the remaining share.
The monthly average for 2021 saw company-developed Wound Care Management pipeline products account for 77% of pipeline products and institute-developed pipeline products account for 23%.
The medical devices pipeline data used in this article were extracted from Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database covers all medical devices which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Pipeline products are covered from various authenticated sources like company websites, SEC filings, conference presentations, analyst presentations, news releases, grants etc. The information is collected by following systematic research techniques and proprietary methodology.